Skip to main content

Table 4 Changes in pre-treatment resting parameters during pulmonary rehabilitation with ghrelin or placebo

From: Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

  Ghrelin, n = 10 Placebo, n = 10 Treatment effect (95% CI; p value)
  Pre-treatment Mean D. Pre-treatment Mean D.  
Body weight (kg) 48.2 (7.4) -0.1 (1.0) 46.8 (7.6) 0.1 (1.3) -0.2 (-1.3 to 0.9; 0.698)
Total lean mass (kg) 37.2 (5.6) 0.1 (2.3) 35.5 (4.7) 0.6 (0.8) -0.5 (-2.1 to 1.2; 0.561)
MEP (cmH20) 77.7 (28.7) 16.2 (15.8) 87.2 (25.6) -6.6 (13.4) 22.8 (7.1 to 38.4; 0.007)
MIP (cmH20) -52.7 (20.8) -10.0 (24.6) -54.2 (15.4) -7.9 (5.4) -2.1 (-22.5 to 18.2; 0.825)
PFT      
FEV1 (L) 0.83 (0.21) 0.06 (0.16) 0.82 (0.23) 0.07 (0.16) -0.01 (-0.16 to 0.13; 0.845)
FEV1/FVC (%) 41.7 (7.6) -1.9 (3.6) 42.4 (8.0) -3.4 (3.8)* 1.5 (-2.1 to 5.0; 0.383)
%FEV1 (%) 32.0 (9.4) 2.1 (6.3) 33.3 (10.5) 2.9 (6.3) -0.8 (-6.8 to 5.1; 0.778)
VC (L) 2.54 (0.42) 0.18 (0.28) 2.62 (0.50) 0.15 (0.20)* 0.03 (-0.20 to 0.26; 0.800)
%VC (%) 79.6 (11.0) 5.5 (8.9) 86.1 (15.3) 4.9 (7.3) 0.6 (-7.1 to 8.2; 0.877)
DLco (%) 61.3 (23.8) 10.0 (37.5) 72.4 (27.4) -6.1 (12.2) 16.1 (-10.1 to 42.3; 0.222)
  1. Data are presented as means (SD) unless otherwise indicated. D Difference from pre-treatment, DLco Carbon monoxide diffusing capacity, FEV 1 Forced Expiratory Volume in one second, FVC Forced Vital Capacity, MEP Maximal Expiratory Pressure, MIP Maximal Inspiratory Pressure, PFT Pulmonary Function Test, Treatment effect Mean Difference (ghrelin minus placebo), VC Vital Capacity. * p < 0.05, *** p < 0.001: change between pre-treatment and post-treatment (within-group difference) by paired t-test. change between pre-treatment and post-treatment (treatment effect) by unpaired t-test. MEP and MIP were tested at pre-treatment and 4 weeks after the completion of the combination treatment.
\